GlassScriptPhysician profile
Glenn M Rich
NPI 1922027259
$209,842.65
in general payments reported to CMS, 2019-2025
57 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $26K · 2021: $18K · 2022: $31K · 2023: $49K · 2024: $32K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Food and Beverage: $5,440 · Travel and Lodging: $4,361 · Consulting Fee: $2,130 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,275.00 |
| Food and Beverage | $5,439.74 |
| Travel and Lodging | $4,361.29 |
| Consulting Fee | $2,130.00 |
| Education | $144.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $124,127.08 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $31,216.71 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30,662.19 | 2019-2024 | Jardiance, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $12,686.24 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $4,314.35 | 2019-2024 | Gardasil 9, Verquvo, Vaxneuvance |
| Amgen INC. | $1,328.98 | 2019-2024 | Otezla, Enbrel, Repatha |
| Abbvie INC. | $805.03 | 2019-2023 | |
| Abbott Laboratories | $533.93 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Mallinckrodt Hospital Products INC. | $386.42 | 2020-2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $351.62 | 2022-2023 | |
| Corcept Therapeutics | $309.18 | 2019-2024 | Korlym |
| Glaxosmithkline, LLC. | $292.49 | 2019-2023 | Benlysta, Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $273.56 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $230.67 | 2019-2022 | |
| Ucb, INC. | $188.72 | 2021-2023 | Cimzia |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.